F2 sirna

F2 siRNA (Human)

Cat. Num. AAA8203985

• Gene Names: F2; PT; THPH1; RPRGL2
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: F2; F2 siRNA (Human); Prothrombin; Coagulation factor II; F2 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: F2 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 622

• Applicable Applications for F2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human F2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for F2 sirna

siRNA to inhibit F2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4503635
• NCBI GeneID: 2147
• NCBI Accession #: NP_000497.1
• NCBI GenBank Nucleotide #: NM_000506.4
• UniProt Accession #: P00734; Q4QZ40; Q53H04; Q53H06; Q69EZ7; Q7Z7P3; Q9UCA1; B2R7F7; B4E1A7
• Molecular Weight: 70,037 Da
• NCBI Official Full Name: prothrombin isoform 1 preproprotein
• NCBI Official Synonym Full Names: coagulation factor II (thrombin)
• NCBI Official Symbol: F2
• NCBI Official Synonym Symbols: PT; THPH1; RPRGL2
• NCBI Protein Information: prothrombin
• UniProt Protein Name: Prothrombin
• Protein Family: Prothrombin
• UniProt Gene Name: F2
• UniProt Entry Name: THRB_HUMAN

NCBI Description

Coagulation factor II is proteolytically cleaved to form thrombin in the first step of the coagulation cascade which ultimately results in the stemming of blood loss. F2 also plays a role in maintaining vascular integrity during development and postnatal life. Peptides derived from the C-terminus of this protein have antimicrobial activity against E. coli and P. aeruginosa. Mutations in F2 lead to various forms of thrombosis and dysprothrombinemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Aug 2015]

Uniprot Description

prothrombin: Thrombin, which cleaves bonds after Arg and Lys, converts fibrinogen to fibrin and activates factors V, VII, VIII, XIII, and, in complex with thrombomodulin, protein C. Functions in blood homeostasis, inflammation and wound healing. Defects in F2 are the cause of factor II deficiency (FA2D). It is a very rare blood coagulation disorder characterized by mucocutaneous bleeding symptoms. The severity of the bleeding manifestations correlates with blood factor II levels. Genetic variations in F2 may be a cause of susceptibility to ischemic stroke (ISCHSTR); also known as cerebrovascular accident or cerebral infarction. A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors. Defects in F2 are the cause of thrombophilia due to thrombin defect (THPH1). It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation. A common genetic variation in the 3-prime untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increased risk of venous thrombosis. Defects in F2 are associated with susceptibility to pregnancy loss, recurrent, type 2 (RPRGL2). A common complication of pregnancy, resulting in spontaneous abortion before the fetus has reached viability. The term includes all miscarriages from the time of conception until 24 weeks of gestation. Recurrent pregnancy loss is defined as 3 or more consecutive spontaneous abortions. Belongs to the peptidase S1 family.

Protein type: Protease; Secreted; Secreted, signal peptide; EC 3.4.21.5; Apoptosis

Chromosomal Location of Human Ortholog: 11p11

Cellular Component: extracellular space; Golgi lumen; endoplasmic reticulum lumen; extracellular region; plasma membrane

Molecular Function: protein binding; growth factor activity; serine-type endopeptidase activity; calcium ion binding; receptor binding

Biological Process: positive regulation of blood coagulation; multicellular organismal development; positive regulation of collagen biosynthetic process; proteolysis; regulation of cell shape; negative regulation of fibrinolysis; cell surface receptor linked signal transduction; positive regulation of cell proliferation; response to wounding; acute-phase response; negative regulation of proteolysis; platelet activation; cytosolic calcium ion homeostasis; post-translational protein modification; positive regulation of cell growth; peptidyl-glutamic acid carboxylation; positive regulation of phosphoinositide 3-kinase cascade; fibrinolysis; cellular protein metabolic process; regulation of gene expression; regulation of blood coagulation; negative regulation of astrocyte differentiation; positive regulation of protein amino acid phosphorylation; positive regulation of release of sequestered calcium ion into cytosol; blood coagulation; blood coagulation, intrinsic pathway; leukocyte migration

Disease: Thrombophilia Due To Thrombin Defect; Stroke, Ischemic; Pregnancy Loss, Recurrent, Susceptibility To, 2; Prothrombin Deficiency, Congenital